Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rebleeding · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Delayed cerebral ischaemia · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hydrocephalus · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death or dependency · people with acute subarachnoid haemorrhage
It is very uncertain whether induced hypertension changes death or dependency (primary outcome) compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Quality of life · people with acute subarachnoid haemorrhage
1 finding from 1 review
Rebleeding · people with acute subarachnoid haemorrhage
1 finding from 1 review
Delayed cerebral ischaemia · people with acute subarachnoid haemorrhage
It is very uncertain whether induced hypertension changes delayed cerebral ischaemia compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Hydrocephalus · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from all causes (primary outcome) · people with acute subarachnoid haemorrhage
It is very uncertain whether lowered blood pressure changes death from all causes (primary outcome) compared with placebo (very low certainty).
1 finding from 1 review
Death or dependency · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (any cause) compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
All cardiovascular death · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower death (cardiovascular) compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
Cardiovascular and cerebrovascular morbidity · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
Hyperkalaemia · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).
1 finding from 1 review
Gynaecomastia · people with chronic kidney disease requiring dialysis
Aldosterone antagonists (spironolactone or eplerenone) probably leads to higher gynaecomastia compared with control (placebo or standard care) (moderate certainty).
1 finding from 1 review
Left ventricular mass · people with chronic kidney disease requiring dialysis
1 finding from 1 review
Failure of PDA closure within 1 week of administration of the first dose of indomethacin · symptomatic patent ductus arteriosus in preterm infants
Indomethacin leads to lower failure of PDA closure within 1 week of administration of the first… compared with placebo or control (high certainty).
1 finding from 1 review